Compound Evidence File
#EC-2026-0508
Telmisartan
Filed under Oral Tablets. The bureau holds 150 laboratory returns for this compound from 58 distinct subjects. Scores below are per-subject aggregates; open a subject row for the underlying evidence.
Cross-Index
Subjects Shipping This Compound
58 SUBJECTS| Subject | Grade | Samples | Mean | Min | Max | First seen | Last seen |
|---|---|---|---|---|---|---|---|
| HomopeptideCASE #VI-2026-0760 | A | 6 | 10.0 | 9.9 | 10.0 | 23 May 2026 | 23 May 2026 |
| Tianjin Finder Chemical TFCCASE #VI-2026-0693 | A | 5 | 10.0 | 10.0 | 10.0 | 14 Nov 2025 | 16 Apr 2026 |
| Shanghai ERP BiotechnologyCASE #VI-2026-0936 | A | 4 | 10.0 | 9.9 | 10.0 | 10 Feb 2026 | 5 Jul 2026 |
| QYAOBIOCASE #VI-2026-0861 | A | 4 | 10.0 | 9.9 | 10.0 | 25 Apr 2026 | 21 Jun 2026 |
| Chinese Peptide CompanyCASE #VI-2026-0184 | A | 4 | 10.0 | 9.9 | 10.0 | 6 Apr 2026 | 3 Jul 2026 |
| Shanghai Sigma AudleyCASE #VI-2026-0505 | A | 4 | 10.0 | 9.9 | 10.0 | 23 Mar 2026 | 8 Jun 2026 |
| Hubei JianxiangCASE #VI-2026-0048 | A | 3 | 10.0 | 9.9 | 10.0 | 21 Feb 2026 | 7 Jul 2026 |
| Sigma-AldrichCASE #VI-2026-0829 | A | 3 | 10.0 | 9.9 | 10.0 | 2 Feb 2026 | 28 Jul 2026 |
| PolyPeptide GroupCASE #VI-2026-0143 | A | 2 | 10.0 | 10.0 | 10.0 | 10 Feb 2026 | 22 Jul 2026 |
| Thermo Fisher ScientificCASE #VI-2026-0142 | A | 2 | 10.0 | 10.0 | 10.0 | 2 Feb 2026 | 25 Apr 2026 |
| SinoPepCASE #VI-2026-0387 | A | 2 | 10.0 | 10.0 | 10.0 | 16 May 2026 | 13 Aug 2026 |
| PeptiSlimCASE #VI-2026-0557 | X | 1 | 10.0 | 10.0 | 10.0 | 3 Jul 2025 | 3 Jul 2025 |
| Flourishglobal PeptideCASE #VI-2026-0630 | A | 4 | 9.9 | 9.9 | 10.0 | 25 Jan 2026 | 28 May 2026 |
| BachemCASE #VI-2026-0314 | A | 3 | 9.9 | 9.9 | 10.0 | 23 Jan 2026 | 10 Jul 2026 |
| Kerui PeptidesCASE #VI-2026-0626 | A | 3 | 9.9 | 9.9 | 10.0 | 23 Dec 2025 | 16 May 2026 |
| Shanghai Wibson BiotechnologyCASE #VI-2026-0379 | A | 3 | 9.9 | 9.9 | 10.0 | 2 Jan 2026 | 3 May 2026 |
| WuXi TIDESCASE #VI-2026-0335 | A | 3 | 9.9 | 9.9 | 10.0 | 23 Jan 2026 | 9 May 2026 |
| Sangon BioCASE #VI-2026-0671 | A | 2 | 9.9 | 9.9 | 9.9 | 25 Nov 2025 | 6 Apr 2026 |
| JEEP PeptidesCASE #VI-2026-0457 | A | 2 | 9.9 | 9.9 | 10.0 | 4 Dec 2025 | 26 Jan 2026 |
| Mokemei BiotechnologyCASE #VI-2026-0540 | A | 2 | 9.9 | 9.9 | 10.0 | 8 Jun 2026 | 23 Jun 2026 |
| Hybio PharmaceuticalCASE #VI-2026-0065 | A | 2 | 9.9 | 9.9 | 10.0 | 4 Feb 2026 | 3 Aug 2026 |
| GenScript PeptidesCASE #VI-2026-0860 | A | 2 | 9.9 | 9.9 | 10.0 | 10 Jan 2026 | 9 Jul 2026 |
| AsymchemCASE #VI-2026-0091 | A | 2 | 9.9 | 9.9 | 10.0 | 1 Jul 2026 | 12 Aug 2026 |
| AmbioPharmCASE #VI-2026-0177 | A | 2 | 9.9 | 9.9 | 10.0 | 17 May 2026 | 19 Aug 2026 |
| Qingdao Hongshengda TradingCASE #VI-2026-0334 | X | 1 | 9.9 | 9.9 | 9.9 | 13 Feb 2025 | 13 Feb 2025 |
| Xingruida XDRCASE #VI-2026-0898 | X | 1 | 9.7 | 9.7 | 9.7 | 17 Dec 2024 | 17 Dec 2024 |
| Pure Tested PeptidesCASE #VI-2026-0225 | X | 1 | 9.7 | 9.7 | 9.7 | 7 May 2025 | 7 May 2025 |
| Glbiochem (Shanghai)CASE #VI-2026-0704 | A | 6 | 9.2 | 7.3 | 10.0 | 24 May 2026 | 24 May 2026 |
| Orbitrex PeptidesCASE #VI-2026-0812 | X | 1 | 9.0 | 9.0 | 9.0 | 3 Jul 2025 | 3 Jul 2025 |
| Peptide PartnersCASE #VI-2026-0295 | X | 3 | 8.8 | 8.2 | 10.0 | 2 Apr 2025 | 21 May 2026 |
| NextechLabsCASE #VI-2026-0285 | X | 2 | 8.8 | 7.5 | 10.0 | 16 Mar 2025 | 20 May 2026 |
| Xingtai Jiachuang TechnologyCASE #VI-2026-0712 | X | 1 | 8.7 | 8.7 | 8.7 | 3 Jun 2025 | 3 Jun 2025 |
| Wuhan Wansheng Bio (WWB)CASE #VI-2026-0594 | A | 2 | 8.6 | 8.1 | 9.2 | 24 May 2026 | 24 May 2026 |
| Bulk Peptide WholesaleCASE #VI-2026-0319 | X | 1 | 8.6 | 8.6 | 8.6 | 25 Apr 2025 | 25 Apr 2025 |
| Shanghai Sigma Audley SSACASE #VI-2026-0486 | A | 4 | 8.3 | 7.7 | 10.0 | 24 May 2026 | 24 May 2026 |
| Polaris PeptidesCASE #VI-2026-0839 | X | 6 | 8.3 | 7.6 | 10.0 | 25 Apr 2025 | 25 May 2026 |
| Mai PeptideCASE #VI-2026-0769 | X | 1 | 8.3 | 8.3 | 8.3 | 3 Jun 2025 | 3 Jun 2025 |
| Nantong Guangyuan Chemical GYCCASE #VI-2026-0284 | A | 3 | 8.2 | 7.5 | 8.9 | 24 May 2026 | 24 May 2026 |
| HazelCASE #VI-2026-0392 | X | 1 | 8.2 | 8.2 | 8.2 | 21 May 2025 | 21 May 2025 |
| NextGen HealthCASE #VI-2026-0604 | X | 1 | 7.8 | 7.8 | 7.8 | 3 Jun 2025 | 3 Jun 2025 |
| Qingdao Sigma Chemical QSCCASE #VI-2026-0538 | A | 6 | 7.7 | 6.0 | 8.7 | 23 May 2026 | 23 May 2026 |
| SRY LabsCASE #VI-2026-0657 | X | 4 | 7.3 | 6.4 | 8.1 | 20 Jun 2025 | 25 May 2026 |
| AKS ChemCASE #VI-2026-0313 | X | 1 | 7.2 | 7.2 | 7.2 | 20 Jun 2025 | 20 Jun 2025 |
| HK PeptidesCASE #VI-2026-0140 | X | 14 | 7.1 | 4.6 | 9.2 | 25 Apr 2025 | 25 May 2026 |
| Zztai PeptideCASE #VI-2026-0192 | C | 2 | 6.9 | 6.1 | 7.7 | 27 Feb 2025 | 25 May 2026 |
| Peptide-SCASE #VI-2026-0111 | X | 5 | 6.9 | 4.9 | 9.5 | 8 Jul 2025 | 25 May 2026 |
| Eternal PeptidesCASE #VI-2026-0842 | X | 2 | 6.7 | 6.3 | 7.1 | 16 Mar 2025 | 21 May 2026 |
| Xingtai Lesda TechnologyCASE #VI-2026-0381 | X | 1 | 6.7 | 6.7 | 6.7 | 28 Mar 2025 | 28 Mar 2025 |
| YB PeptideCASE #VI-2026-0813 | X | 1 | 6.6 | 6.6 | 6.6 | 21 May 2025 | 21 May 2025 |
| Hangzhou Mandy BiotechnologyCASE #VI-2026-0695 | X | 1 | 6.6 | 6.6 | 6.6 | 25 Apr 2025 | 25 Apr 2025 |
| Bio PepzCASE #VI-2026-0436 | X | 1 | 6.0 | 6.0 | 6.0 | 24 Apr 2025 | 24 Apr 2025 |
| Eros PeptidesCASE #VI-2026-0918 | X | 1 | 5.8 | 5.8 | 5.8 | 28 Mar 2025 | 28 Mar 2025 |
| Kerisite Shenzhen InternationalCASE #VI-2026-0315 | X | 1 | 5.2 | 5.2 | 5.2 | 28 Mar 2025 | 28 Mar 2025 |
| Nanjing Xiyuxun Technology XYXCASE #VI-2026-0433 | X | 1 | 5.2 | 5.2 | 5.2 | 21 May 2025 | 21 May 2025 |
| Biolabshop LimitedCASE #VI-2026-0832 | X | 1 | 5.1 | 5.1 | 5.1 | 25 Apr 2025 | 25 Apr 2025 |
| Dragon PharmaCASE #VI-2026-0519 | X | 1 | 4.2 | 4.2 | 4.2 | 6 May 2025 | 6 May 2025 |
| PeptiLab ResearchCASE #VI-2026-0267 | X | 1 | 1.9 | 1.9 | 1.9 | 27 Feb 2025 | 27 Feb 2025 |
| Guangzhou Yuao TradingCASE #VI-2026-0787 | X | 1 | 1.4 | 1.4 | 1.4 | 3 Jul 2025 | 3 Jul 2025 |
Open any subject to view the batch-level evidence for Telmisartan alone.